Regeneron’s Inmazeb becomes first drug to be approved by the FDA for Ebola

The cocktail of three monoclonal antibodies becomes the first to be approved for treatment of the virus which killed thousands across West Africa.

With news surrounding Covid-19 candidates dominating headlines for much of the week, one could have easily missed the positive news that emerged on the Ebola treatment front. Regeneron’s Inmazeb was approved on Thursday for the treatment of Ebola – the first drug to receive the green light for the virus which wreaked havoc across West Africa following the 2014-2016 outbreak – the largest on record.

Inmazeb – a cocktail of three monoclonal antibodies (atoltivimab, maftivimab, and odesivimab-ebgn) which was developed using the same rapid response technologies as the company’s Covid-19 antibody combination was approved for treatment of the infection in adult and pediatric patients, including newborns of Ebola-positive mothers and is expected to be rolled out across the US over the coming years on the back of the company’s US$345 million deal with BARDA.